Scilex Holding Company Announces Its Board of Directors Approved a Dividend of Dream Bowl I Meme Coin Tokens to Holders of Common Stock and other Eligible Equity Securities with a Record Date of April 30, 2026
Rhea-AI Summary
Scilex Holding Company (Nasdaq: SCLX) announced a dividend of Dream Bowl I meme coin tokens to holders of common stock and other eligible equity securities with a record date of April 30, 2026.
Participating holders will receive 5 Dream Bowl Tokens per share. Scilex holds ~268 million tokens and plans to distribute ~81.4 million. Payment will occur within 60 days after the record date, subject to Board discretion and an opt-in wallet process with Datavault.
Positive
- Dividend of Dream Bowl tokens approved for shareholders
- Distribution ratio set at 5 tokens per share
- Scilex to distribute approximately 81.4 million tokens
Negative
- Payment conditional on Board not revoking distribution
- Dream Bowl Tokens may have no value
- Participating holders must opt in and open a Datavault wallet
News Market Reaction – SCLX
In the Apr 20 session, SCLX gained 0.65%, reflecting a mild positive market reaction. Argus tracked a peak move of +3.6% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | Strategic investment | Positive | -2.0% | Announced a $20M strategic investment in Quantum Scan diagnostic platforms. |
| Jan 02 | Legal counsel appointment | Positive | +7.3% | Appointed Kasowitz LLP as litigation and IP counsel to support assets. |
| Dec 23 | Meme coin claim process | Positive | -8.2% | Confirmed Dream Bowl 2026 meme coin claim process for eligible holders. |
| Nov 26 | Datavault AI financing | Positive | +0.4% | Closed second tranche Datavault AI equity financing via large pre-funded warrant. |
| Nov 25 | Warrant exercises | Positive | -8.0% | Closed reduced-price warrant exercises raising $20.3M gross proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news has often been framed as strategically positive, but price reactions have been mixed, with several positive corporate or token-related announcements followed by negative 24-hour moves.
Over the last six months, SCLX has focused on strategic financings, AI/data partnerships, and token-related shareholder perks. A $20 million strategic investment in Quantum Scan and a large Datavault AI equity position underline a data/AI strategy, while warrant exercises raised $20.3 million in cash. Prior Dream Bowl meme coin communications drew a negative price reaction of -8.2%, showing that digital-asset themed news has not consistently supported the share price. Today’s token dividend fits into this broader AI/tokenization narrative.
Key Terms
digital wallet technical
cryptocurrency exchange technical
digital collectible technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PALO ALTO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease, today announced that its Board of Directors (the “Scilex Board”) approved a dividend of Dream Bowl I Meme Coin Tokens held by the Company (the “Dream Bowl Tokens”) to its stockholders and certain other eligible equityholders of Scilex (collectively, the “Participating Holders”). The record date for the Dividend is April 30, 2026 (the “Record Date”).
The Participating Holders as of the Record Date will be entitled to receive five (5) Dream Bowl Tokens for each share of Scilex common stock held (or for each share of common stock issuable or deemed issuable upon exercise or conversion of such other eligible securities). Scilex currently holds approximately 268 million Dream Bowl Tokens and plans to distribute approximately 81.4 million of such Dream Bowl Tokens to the Participating Holders.
The Record Date for the dividend may be changed by the Scilex Board for any reason at any time prior to the actual payment date, and payment of the dividend is conditioned upon the Scilex Board having not revoked the dividend prior to the payment date, including for a material change to the solvency or surplus analysis presented to the Scilex Board. Subject to the right of the Scilex Board to change the Record Date, the payment date for the dividend will be determined by subsequent resolutions of the Scilex Board, which payment date will be within 60 days following the Record Date (the “Payment Date”).
It is anticipated that in order to receive the Dream Bowl Tokens, the Participating Holders will be required to open a digital wallet with Datavault AI Inc. (“Datavault”) and execute an Opt-In Agreement, pursuant to which such holders will agree, among other things, to the payment conditions set forth therein, and acknowledge that such holders understand the process for receiving the Dream Bowl Tokens, that the Scilex Board can change the Record Date or Payment Date or revoke the distribution prior to the Payment Date, and that the Dream Bowl Tokens may not have or maintain any value.
The Company will provide further instructions regarding wallet setup, token access, and distribution process in a subsequent communication prior to the Payment Date to ensure that all eligible Participating Holders can properly claim and view their tokens.
Scilex intends to list the Dream Bowl Tokens on the Biconomy exchange ("Biconomy" – biconomy.com), a global centralized cryptocurrency exchange at a later date. Scilex believes that such listing may deliver liquidity and allow for broad distribution of such tokens for the Participating Holders.
The Dream Bowl Token is a digital collectible intended solely for personal, non-commercial use. The Dream Bowl Token does not in and of itself: (i) represent or confer any equity, voting, dividend, profit-sharing, or ownership rights in Scilex or any other entity (including Datavault); (ii) provide any right to receive monetary payments, distributions, or appreciation; or (iii) create any expectation of profit or reliance on the managerial or entrepreneurial efforts of Scilex or others. The Dream Bowl Token is not designed or intended to function as an investment, currency, or financial product, and it is not being offered, sold, or distributed for fundraising or capital-raising purposes. Use of the Dream Bowl Token is limited to entertainment, event-access, and digital-collectible functions. Any transferability features are provided solely to support personal digital item portability and not to facilitate or imply investment or speculative use.
For more information on Scilex Holding Company, refer to www.scilexholding.com
For more information on Semnur Pharmaceuticals, Inc., refer to www.semnurpharma.com
For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com.
For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com.
For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com.
https://www.facebook.com/scilex.pharm
https://www.linkedin.com/company/scilex-holding-company/
About Scilex Holding Company
Scilex is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system)
In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA” or “SP-102”), which is owned by Semnur (a majority owned subsidiary of Scilex) and is a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system)
Scilex is headquartered in Palo Alto, California.
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts and may be accompanied by words that convey projected future events or outcomes, such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” or variations of such words or by expressions of similar meaning. These forward-looking statements include, but are not limited to, statements regarding future events, including Scilex’s potential distribution of the Dream Bowl Tokens and the timing thereof (including that the Payment Date will be determined by subsequent resolutions of the Scilex Board, and that the Scilex Board may change the Record Date and, as a result, the Payment Date, once determined) and the Company’s intention to deliver liquidity and broad distribution of the Dream Bowl Tokens. These statements are based on management’s current expectations and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Scilex. These statements are subject to a number of risks and uncertainties regarding Scilex’s business. These risks and uncertainties include, but are not limited to, risks related to legal proceedings that may be instituted against Scilex regarding the Dream Bowl Tokens and the distribution thereof to the Company’s eligible equityholders; risks associated with the right of the Scilex Board to change the Record Date and the Payment Date of the distribution of, and/or to revoke, the dividend of the Dream Bowl Tokens; general economic, political and business conditions; the ability of Scilex and its subsidiaries to develop and successfully market products; the ability of Scilex and its subsidiaries to grow and manage growth profitably and retain its key employees; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the prior results of the clinical trials may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks set forth in Scilex’s filings with the SEC. There may be additional risks that Scilex presently does not know or that Scilex currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Scilex’s expectations, plans or forecasts of future events and views as of the date of the communication. Scilex anticipates that subsequent events and developments will cause such assessments to change. However, while Scilex may elect to update these forward-looking statements at some point in the future, Scilex specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Scilex’s assessments as of any date subsequent to the date of this communication. Accordingly, investors are cautioned not to place undue reliance on these forward-looking statements.
Contacts:
Investors and Media
Scilex Holding Company
960 San Antonio Road
Palo Alto, CA 94303
Office: (650) 516-4310
Email: investorrelations@scilexholding.com
Website: www.scilexholding.com
SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a majority-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.
ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.
Gloperba® is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.
ELYXYB® is a registered trademark owned by Scilex Holding Company.
Scilex Bio™ is a trademark owned by Scilex Holding Company, Inc.
All other trademarks are the property of their respective owners.
© 2026 Scilex Holding Company All Rights Reserved.
